Optimization and validation of a flow cytometry‐based HLA ‐ B27 assay on BD FACSLyric
Cytometry Part B: Clinical Cytometry · 2026-09 · 110 (5) · 380-387
DOI: 10.1002/cyto.b.70031 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Cytometry Part B: Clinical Cytometry, online erschienen am 08.04.2026. Verfasst von Azzeddine Tahiat und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Rouiba Hospital, Algiers, Algeria. Hauptthemen laut MEDLINE: Flow Cytometry, HLA-B27 Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
The BD ™ HLA ‐ B27 GS145 .2‐based assay for flow cytometric HLA ‐ B27 typing has been validated on earlier‐generation cytometers but not on the increasingly adopted BD FACSLyric platform, highlighting the need for platform‐specific validation. While prior transfer strategies relied on conversion of the source instrument's parameters, we performed a de novo analytical validation of the HLA ‐ B27 Kit on the FACSLyric . Our strategy encompassed determination of the assay's gray zone and rigorous evaluation of analytical performance following CLSI H62 guidelines. A total of 125 patient samples were analyzed in parallel by real‐time PCR ( RT ‐ PCR ) and flow cytometry. Sixteen patients (12.8%) were HLA ‐ B27 positive by RT ‐ PCR . A ROC ‐derived mean fluorescence intensity ( MFI ) cut‐off of 6627 achieved 100% sensitivity and 99.1% specificity. The empirically defined gray zone (6627–7073) was narrow, encompassing only two samples. To strengthen analytical robustness, bootstrapping was applied to derive a 95% confidence interval around the cut‐off, yielding an expanded gray zone of 5779–7327. Using this interval, 7 samples (5.6%) were classified as equivocal, comprising four HLA ‐ B27 ‐positive cases and three samples carrying cross‐reactive alleles ( HLA ‐B*42, HLA ‐B*37, and HLA ‐B*44). Outside the gray zone, flow cytometry showed complete concordance with RT ‐ PCR . MFI values above 7327 ensured unequivocal HLA ‐ B27 positivity with 100% specificity. Precision was high (intra‐assay 5.43%, between‐run 1.84%, between‐day 5.13%), with no carryover and reliable typing up to 24 h post‐collection. These results establish a robust, reproducible, and scalable framework for accurate first‐line HLA ‐ B27 detection on the FACSLyric platform.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biology, Rouiba Hospital, Algiers, Algeria.
- Algiers University of Health Sciences, Algiers, Algeria.
- Histocompatibility and Immunogenetics Laboratory, Department of Immunology, Institut Pasteur d'Algérie, Algiers, Algeria.
- Department of Immunology, Institut Pasteur d'Algérie, Algiers, Algeria.
ORCID-Profile: Azzeddine Tahiat
Zitieren
APA
Tahiat, A., Meçabih, F., Boumzou, H., Benkortbi, H., Attal, N., & Djenouhat, K. (2026). Optimization and validation of a flow cytometry‐based HLA ‐ B27 assay on BD FACSLyric. Cytometry Part B: Clinical Cytometry, 110(5), 380-387. https://doi.org/10.1002/cyto.b.70031
Vancouver
Tahiat A, Meçabih F, Boumzou H, Benkortbi H, Attal N, Djenouhat K. Optimization and validation of a flow cytometry‐based HLA ‐ B27 assay on BD FACSLyric. Cytometry Part B: Clinical Cytometry. 2026;110(5):380-387. doi:10.1002/cyto.b.70031
BibTeX
@article{Tahiat2026,
author = {Tahiat, Azzeddine and Meçabih, Fethi and Boumzou, Houssam and Benkortbi, Halla and Attal, Nabila and Djenouhat, Kamel},
title = {Optimization and validation of a flow cytometry‐based HLA ‐ B27 assay on BD FACSLyric},
journal = {Cytometry Part B: Clinical Cytometry},
year = {2026},
volume = {110},
number = {5},
pages = {380--387},
doi = {10.1002/cyto.b.70031}
}
EUVIMED